The long-acting insulin, known as U300, requires less frequent or lower dosing than Lantus and offers a more consistent insulin release.

 

An improved version of Sanofi’s Lantus diabetes drug is better than the old one at controlling blood sugar levels and comes with fewer hypoglycemic events, new late-stage trial data showed on Tuesday.

The treatment is one of several drugs Sanofi is betting on to defend its No.2 spot on the world’s $42 billion diabetes market as its star product Lantus, the world’s most prescribed insulin, will lose patent protection by 2015.

The long-acting insulin, known as U300, requires  ..